BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24335566)

  • 41. [Differential diagnosis of brain gliomas by positron emission tomography using various radiopharmaceuticals].
    Kostenikov NA; Tiutin LA; Fadeev NP; Panfilenko AF; Zykov EM; Iliushchenko IuR; Makeeva OIu
    Vestn Rentgenol Radiol; 2014; (5):13-8. PubMed ID: 25775890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging.
    Stadlbauer A; Prante O; Nimsky C; Salomonowitz E; Buchfelder M; Kuwert T; Linke R; Ganslandt O
    J Nucl Med; 2008 May; 49(5):721-9. PubMed ID: 18413402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.
    Santra A; Kumar R; Sharma P; Bal C; Kumar A; Julka PK; Malhotra A
    Eur J Radiol; 2012 Mar; 81(3):508-13. PubMed ID: 21353420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.
    Bisdas S; Ritz R; Bender B; Braun C; Pfannenberg C; Reimold M; Naegele T; Ernemann U
    Invest Radiol; 2013 May; 48(5):295-301. PubMed ID: 23296081
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
    Karunanithi S; Sharma P; Kumar A; Gupta DK; Khangembam BC; Ballal S; Kumar R; Kumar R; Bal C
    Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
    Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
    J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas.
    Gumprecht H; Grosu AL; Souvatsoglou M; Dzewas B; Weber WA; Lumenta CB
    Zentralbl Neurochir; 2007 Feb; 68(1):19-23. PubMed ID: 17487804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
    Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
    J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
    Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC
    Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy.
    Maurer T; Souvatzoglou M; Kübler H; Opercan K; Schmidt S; Herrmann K; Stollfuss J; Weirich G; Haller B; Gschwend JE; Schwaiger M; Krause BJ; Treiber U
    Eur Urol; 2012 May; 61(5):1031-8. PubMed ID: 22196847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Value of ¹⁸F-FDG PET/CT in the diagnosis of primary gastric cancer via stomach distension.
    Ma Q; Xin J; Zhao Z; Guo Q; Yu S; Xu W; Liu C; Zhai W
    Eur J Radiol; 2013 Jun; 82(6):e302-6. PubMed ID: 23434453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
    Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
    Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results.
    Sadeghi N; Salmon I; Tang BN; Denolin V; Levivier M; Wikler D; Rorive S; Balériaux D; Metens T; Goldman S
    J Magn Reson Imaging; 2006 Nov; 24(5):989-94. PubMed ID: 17031832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.